Skip to main
CNTB

CNTB Stock Forecast & Price Target

CNTB Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Connect Biopharma Hldgs is poised for success with its promising next-generation antibody, rademikibart, which has shown positive results in clinical trials for asthma and COPD and has received an Outperform rating and $8 price target. The drug's unique mechanism and potential in the Chinese market provide a strong foundation for financial growth, with potential peak revenue of $2 billion upon FDA approval. With upcoming Phase 2 studies and an expanding pipeline, the company is on track for significant success.

Bears say

Connect Biopharma Hldgs is playing the high-risk, high-reward game with its clinical studies of rademikibart, and their portfolio diversification is currently heavily reliant on its success. However, the differentiation of rademikibart may not be convincing enough, considering that its early signs of efficacy are from uncontrolled and cross-study evidence and the general skepticism around using biologics for acute care. With its sole lead candidate being tested in acute settings, any negative results from the ongoing clinical trials pose a significant risk to the company and its stock value.

CNTB has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Connect Biopharma Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Connect Biopharma Holdings (CNTB) Forecast

Analysts have given CNTB a Strong Buy based on their latest research and market trends.

According to 7 analysts, CNTB has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Connect Biopharma Holdings (CNTB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.